Does Seasonique (ethinyl estradiol/levonorgestrel) cause depression and lower follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does Seasonique Cause Depression and Lower FSH/LH Levels?

Seasonique (ethinyl estradiol/levonorgestrel) does suppress FSH and LH levels as its primary mechanism of action, but the evidence linking combined oral contraceptives to depression is insufficient to establish a clear causal relationship.

Suppression of FSH and LH

Combined oral contraceptives like Seasonique reliably suppress gonadotropin secretion—this is how they prevent pregnancy. 1, 2

  • Seasonique works by inhibiting gonadotropin-releasing hormone (GnRH), which subsequently suppresses both follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This prevents ovulation by blocking the normal hormonal cascade needed for follicular development and egg release. 1, 2

  • Multiple studies demonstrate that ethinyl estradiol/levonorgestrel combinations significantly depress serum FSH and LH levels, particularly by day 20 of the treatment cycle. 3, 4, 5

  • Research specifically on low-dose triphasic preparations containing ethinyl estradiol and levonorgestrel shows significant suppression of both gonadotropins, with LH and FSH levels markedly reduced during treatment. 3, 4

  • The suppression is intentional and therapeutic—it's the mechanism that prevents ovulation and provides contraceptive efficacy. 2, 6

  • Studies show that FSH and LH suppression is time-dependent and may vary individually, with some women showing considerable follicular activity despite treatment (36% in one study), though contraceptive efficacy remains high. 3

Important Clinical Context

  • This is NOT hypogonadism or pathologic hormone deficiency. While Seasonique suppresses endogenous estradiol production from the ovaries, it simultaneously provides exogenous synthetic estrogen (ethinyl estradiol) that maintains adequate estrogenic effects throughout the body. 2

  • The synthetic ethinyl estradiol is significantly more potent than natural estradiol and provides sufficient estrogenic activity to maintain bone health, cardiovascular function, and other estrogen-dependent processes despite lower serum estradiol levels. 2

  • After discontinuation, normal ovarian function typically resumes, with ovulatory patterns reestablished in most women within one cycle. 6

Depression and Combined Oral Contraceptives

The current evidence does NOT establish a clear causal link between combined oral contraceptives and depression, though this remains an area requiring further investigation.

  • No high-quality guidelines or studies in the provided evidence directly address depression as a side effect of Seasonique or similar combined oral contraceptives containing ethinyl estradiol and levonorgestrel.

  • The safety profile of extended-regimen oral contraceptives like Seasonique (which contains 30 mcg ethinyl estradiol/150 mcg levonorgestrel for 84 days followed by 10 mcg ethinyl estradiol for 7 days) shows the regimen is "safe and well tolerated," though specific psychiatric adverse effects were not detailed in the efficacy trials. 7

Clinical Considerations

  • If a patient reports new-onset or worsening depression while taking Seasonique, this warrants clinical attention and consideration of alternative contraceptive methods. Individual responses to hormonal contraceptives vary considerably.

  • Progestin-only contraceptives may have different effects than combined preparations, though the evidence provided does not specifically address depression risk with either formulation. 1

  • Women with pre-existing mood disorders or depression history should be monitored when initiating any hormonal contraceptive, though definitive evidence-based guidance on this specific scenario is lacking in the provided literature.

Related Questions

What does low FSH, LH, and Estradiol indicate in a 43-year-old on medication?
What is the significance of a 50-year-old female's menstrual irregularity, with periods occurring every 2 weeks, in the context of her laboratory results: Luteinizing Hormone (LH) 2.9 milli-international units per milliliter (mIU/mL), Prolactin 8.33 nanograms per milliliter (ng/mL), Follicle Stimulating Hormone (FSH) 7.3 mIU/mL, and Estradiol 119 picograms per milliliter (pg/mL)?
How do Oral Contraceptive Pills (OCPs) affect Follicle-Stimulating Hormone (FSH) and blood hormone levels in women?
Is there any value in assessing Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) and estradiol levels in a female patient of reproductive age taking Tri Cyclen Lo (norgestimate and ethinyl estradiol)?
What is the recommended course of action for a patient with LH 2.4, FSH 2.8, and estradiol 55?
How should I document a patient’s request for discharge against medical advice when imaging shows bilateral cholesteatoma with intracranial extradural extension, extensive sinonasal disease with possible invasive fungal sinusitis, a left antrochoanal polyp causing ostiomeatal obstruction, and cerebral atrophy out of proportion to age?
What is the diagnosis and recommended management for a retrocerebellar cyst with flattening or hypoplasia of the inferior vermis?
How can I calculate total body water, total body potassium, potassium deficit, and determine the appropriate intravenous (IV) and oral potassium replacement (including solution concentration, infusion rate, and monitoring) for a 70‑kg adult male with serum potassium of 2.5 mEq/L (moderate hypokalemia) targeting 4.0 mEq/L?
Can an older woman who has had two recent fainting episodes experience syncope or presyncope during the transition from supine to sitting?
How does atomoxetine work in the treatment of attention‑deficit/hyperactivity disorder?
How do I interpret a pulmonary function test (PFT) study in an adult?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.